Fibrinolytic or anti-plasmin (nafamostat) therapy for COVID-19: A timing challenge for clinicians
| Autor: | Brant M. Wagener, Runzhen Zhao, Hong-Long Ji, Timothy J. Ness |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Pulmonary and Respiratory Medicine
2019-20 coronavirus outbreak Coronavirus disease 2019 (COVID-19) business.industry Plasmin Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Biochemistry (medical) COVID-19 Guanidines Article Benzamidines COVID-19 Drug Treatment Fibrinolytic therapy anti-protease Nafamostat Immunology Humans Medicine Pharmacology (medical) Fibrinolysin business plasmin medicine.drug Anti proteases |
| Zdroj: | Pulmonary Pharmacology & Therapeutics |
| ISSN: | 1094-5539 |
| DOI: | 10.1016/j.pupt.2021.102055 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect